This chapter presents a concise review of Wnt signaling in cancer pathogenesis. Our focus is on the description of novel agents in preclinical and/or clinical stage development, which inhibit dysfunctional Wnt signaling. We discuss growing evidence that the Wnt pathway supports cellular proliferation by sustaining renewal of cancer initiating stem cells. We also review ongoing therapeutic efforts to inhibit pathway activity in a broad range of cancers. The rationale for targeting this pathway is well justified, based on the association of colorectal cancer with deregulation of Wnt signaling. Therefore, the Wnt pathway may represent an important target for the development of novel anticancer therapeutics.
|Original language||English (US)|
|Title of host publication||Signaling Pathways in Cancer Pathogenesis and Therapy|
|Publisher||Springer New York|
|Number of pages||14|
|ISBN (Print)||1461412153, 9781461412151|
|State||Published - Aug 1 2013|
ASJC Scopus subject areas